Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: J Immunol. 2014 May 14;192(12):5802–5812. doi: 10.4049/jimmunol.1301898

FIGURE 6. Neutralization against the SF162 virus is targeted to the V3 region in majority of animals.

FIGURE 6

IgG from animals from the first study were assessed for their capacity to neutralize HIV-1SF162 in the TZM-bl assay in the presence of blocking peptides and representative individual results are displayed. IgG were purified from sera two weeks after the second SIVmac239 gp140 boost. Percent neutralization is depicted on the y-axis and concentration of purified IgG on the x-axis.

(A) Neutralization is displayed for three representative individual animals in the absence (black) or presence of a peptide covering the V3 region from HIV-1 clade B virus MN.3 (dark grey) or a scrambled control peptide (light grey). Peptide controls without IgG did not result in significant enhancement or neutralization of the virus (Suppl. Fig. 2)

(B) Pooled analysis of the neutralization (no peptide, white) and inhibition by a short V3 peptide from clade A containing the GPGQ motif (light grey) or clade B containing the GPGR motif (dark grey), respectively. Results from peptide inhibition without IgG as well as control neutralization using pre-immunization IgG in combination with the peptides (wk 0) did not show significant enhancement or neutralization of the virus. Significant values are indicated by *** p<0.001, **p<0.01 and *p<0.05 as well as ns=not significant using a two-way repeated measures ANOVA with a Bonferroni’s Multiple Comparison Test.